Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer: Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial

Maria Ekholm, Pär Ola Bendahl, Mårten Fernö, Bo Nordenskjöld, Olle Stål, Lisa Rydén

Research output: Contribution to journalArticlepeer-review

20 Citations (SciVal)

Search results